AIM ImmunoTech (NYSE:AIM – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.
Risk and Volatility
AIM ImmunoTech has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for AIM ImmunoTech and Taysha Gene Therapies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AIM ImmunoTech | 0 | 0 | 2 | 0 | 3.00 |
| Taysha Gene Therapies | 0 | 0 | 8 | 0 | 3.00 |
Valuation and Earnings
This table compares AIM ImmunoTech and Taysha Gene Therapies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AIM ImmunoTech | $190,000.00 | 72.17 | -$28.96 million | ($0.47) | -0.46 |
| Taysha Gene Therapies | $9.92 million | 36.38 | -$111.57 million | $0.63 | 2.79 |
AIM ImmunoTech has higher earnings, but lower revenue than Taysha Gene Therapies. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by company insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares AIM ImmunoTech and Taysha Gene Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AIM ImmunoTech | -12,594.21% | -421.73% | -147.54% |
| Taysha Gene Therapies | -229.67% | -106.36% | -49.16% |
Summary
Taysha Gene Therapies beats AIM ImmunoTech on 10 of the 13 factors compared between the two stocks.
About AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.
